Spondyloarthropathy Susceptibility To 3 C2750474
Another genetic susceptibility to inflammatory spine and joint disease. Requires monitoring for signs of arthritis. Management includes anti-inflammatory medications and physical therapy.
Key facts at a glance
- ICD-10
- M35.9
- ICD-11
- FA00.0
- Body system
- musculoskeletal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Inflammatory back pain
(musculoskeletal)Joint pain or stiffness
(musculoskeletal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Sacroiliitis
(musculoskeletal)Peripheral arthritis
(musculoskeletal)Enthesitis
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
NSAID therapy
Nonsteroidal anti-inflammatory drugs are used as first-line pharmacological treatment to reduce inflammation, pain, and stiffness in affected joints and the spine.
Structured exercise program
Supervised physical therapy focusing on flexibility, strengthening, and posture improvement to maintain spinal mobility and prevent stiffness.
Additional treatment options
Biologic DMARDs
TNF-alpha inhibitors or IL-17 inhibitors prescribed when conventional therapy fails to control disease activity and prevent joint damage.
medicationPosture and ergonomics training
Education on proper body mechanics, workstation setup, and sleeping positions to reduce spinal strain and improve daily function.
lifestyleRegular disease activity assessment
Periodic clinical evaluation and imaging to monitor disease progression, treatment response, and detect complications early.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Spondyloarthropathy Susceptibility To 3 C2750474?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
van der Heijde D, Braun J, Deodhar A. 2022 American College of Rheumatology/Spondylitis Association of America Guideline for the Treatment of Axial Spondyloarthritis. Arthritis Rheumatol. 2022.
Sieper J, Poddubnyy D, Sorensen J. New insights into spondyloarthritis pathophysiology and treatment. Nat Rev Rheumatol. 2021.
Dougados M, Combe B, Goupille P. Efficacy and safety of secukinumab in patients with axial spondyloarthritis: Results from the MEASURE trials. Ann Rheum Dis. 2020.
Khan MA, Akkoc N,erve T. Genetic architecture of ankylosing spondylitis and related spondyloarthropathies. Lancet Rheumatol. 2023.
Medication Comparisons
Compare medications used to treat Spondyloarthropathy Susceptibility To 3 C2750474. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy